Verici Dx (FRA:63V) Stock Based Compensation: €0.19 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Stock Based Compensation?

Verici Dx FRA:63V -20.00% Stock Based Compensation is €0.19 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Verici Dx's Stock Based Compensation for the six months ended in Dec. 2025 was €0.08 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.19 Mil.

Verici Dx Stock Based Compensation Related Terms

Verici Dx Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Verici Dx's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Stock Based Compensation Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.66 0.30 0.42 0.03 0.19

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.33 0.03 -0.00 0.11 0.08

Verici Dx Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.19 Mil.

What does a Stock Based Compensation of €0.19 Mil mean?
Verici Dx (FRA:63V) has a Stock Based Compensation of €0.19 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Verici Dx and its competitors.
Is Verici Dx's Stock Based Compensation too high?
Verici Dx's current Stock Based Compensation is €0.19 Mil.
How does Verici Dx's Stock Based Compensation compare to TMO and DHR?
Verici Dx's Stock Based Compensation of €0.19 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Verici Dx and its competitors. Verici Dx's current Stock Based Compensation is €0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (FRA:63V) has a current Stock Based Compensation of €0.19 Mil. The current Stock Based Compensation is €0.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Verici Dx (FRA:63V), the current Stock Based Compensation is €0.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges VRCI:UK
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.